2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2651

Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Abstract Number: 2801

Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus
Abstract Number: 2528

Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Abstract Number: 3246

Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Abstract Number: 2299

Predictors of Mortality in People with Recent Onset of Gout: A Prospective Observational Study
Abstract Number: 1352

Predictors of Mortality in Rheumatic Disease Patients with CMV Infection
Abstract Number: 3088

Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Abstract Number: 1679

Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry
Abstract Number: 2811

Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Abstract Number: 2905

Predictors of Poor Hand Function in Systemic Sclerosis
Abstract Number: 1266

Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated By an Aggressive Treat-to-Target Regimen
Abstract Number: 1882

Predictors of Response to Methotrexate in Patients with Eosinophilic Fasciitis (Shulman’s Disease)
Abstract Number: 2804

Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years
Abstract Number: 713

Predictors of Treatment Retention Among Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Remicade® (Infliximab) for Long-Term in Canadian Real-World
Abstract Number: 580

Preferential Distribution of M1 Monocytes in Anti-Cyclic Citrullinated Peptide Antibody Positive Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].